Magenta Therapeutics is a clinical-stage biotechnology company developing medicines for patients with autoimmune diseases, blood cancers and genetic diseases. The company is developing a suite of antibody-drug conjugates (ADCs), for conditioning. The company's main conditioning product candidate, MGTA-117, is designed to specifically remove disease-causing hematopoietic stem cells and genetically mutated cells. The company's third ADC-based conditioning program, C300, targets T cells, a type of immune cell. The company is also developing MGTA-145 as the standard of care for stem cell mobilization in a range of diseases, including autoimmune diseases, genetic diseases and blood cancers.
- ExchangeNASDAQ Stock Market
- SectorPharmaceuticals & Biotechnology
- CountryUnited States